Amlodac adds to the current Zydus generic portfolio in South Africa (fluoxetine, paroxetine, tramadol, meloxicam and ranitidine) and will be the first of many early-to-market Zydus generics.
Amlodac is indicated for angina and mild to moderate hypertension. Recent revisions to hypertension treatment guidelines have clearly elevated the role of calcium-channel blockers, such as Amlodac. The ASCOT-BPLA trial has specifically demonstrated that a regimen starting with amlodipine besylate is better at reducing total cardiovascular events and procedures, fatal and non-fatal stroke, and the risk of new-onset diabetes.
Amlodac introduces a cost-effective treatment option for new hypertensives and the perfect generic switch for patients established on the original amlodipine besylate.
The Zydus product range is promoted in South Africa by Dr Reddy's.
Enquiries: Shirley Holmes, tel (011) 447-3215 , cell 082 375 3116.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Pulse: The heartbeat of the marketplace|
|Publication:||CME: Your SA Journal of CPD|
|Article Type:||Brief article|
|Date:||May 1, 2007|
|Previous Article:||Tri-Flora hails a new era in probiotics.|
|Next Article:||New vaccine candidate for cervical cancer.|